# Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

> **NCT05321862** · PHASE2 · WITHDRAWN · sponsor: **Nantes University Hospital**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** [68Ga]Ga-PentixaFor

## Key facts

- **NCT ID:** NCT05321862
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-14
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** MIDAS inclusions terminated before first inclusion in PENTI-MIDAS
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321862, "Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05321862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*